Ambalal Sarabhai Enterprises Ltd vs Sun Pharma Advanced Research Company Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 18, 2026

Key Highlights

The Latest Trading Price of Ambalal Sarabhai Enterprises Ltd is ₹ 31.26 as of 18 May 15:30 . The P/E Ratio of Ambalal Sarabhai Enterprises Ltd changed from 4.6 on March 2021 to 54.8 on March 2025 . This represents a CAGR of 64.14% over 5 yearsThe P/E Ratio of Sun Pharma Advanced Research Company Ltd changed from -14 on March 2025 to -14 on March 2025 . This represents a CAGR of 0.00% over 1 years The Market Cap of Ambalal Sarabhai Enterprises Ltd changed from ₹ 135.26 crore on March 2021 to ₹ 268.6 crore on March 2025 . This represents a CAGR of 14.71% over 5 yearsThe Market Cap of Sun Pharma Advanced Research Company Ltd changed from ₹ 5823 crore on March 2023 to ₹ 4802 crore on March 2025 . This represents a CAGR of -6.22% over 3 years The revenue of Ambalal Sarabhai Enterprises Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 revenue of ₹ 54.76 crore. This represent the decline of -100% The revenue of Sun Pharma Advanced Research Company Ltd for the Mar '26 is ₹ 1855 crore as compare to the Dec '25 revenue of ₹ 8.45 crore. This represent the growth of 21852% The ebitda of Ambalal Sarabhai Enterprises Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 ebitda of ₹ 6.02 crore. This represent the decline of -100% The ebitda of Sun Pharma Advanced Research Company Ltd for the Mar '26 is ₹ 1775 crore as compare to the Dec '25 ebitda of ₹ -69 crore. This represent the decline of -2672% The net profit of Ambalal Sarabhai Enterprises Ltd changed from ₹ 0.35 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of -100.00% The net profit of Sun Pharma Advanced Research Company Ltd changed from ₹ -95.9 crore to ₹ 1761 crore over 8 quarters. This represents a CAGR of NaN% The Dividend Payout of Ambalal Sarabhai Enterprises Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Sun Pharma Advanced Research Company Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Ambalal Sarabhai Enterprises Ltd

Ambalal Sarabhai Enterprises Limited, incorporated on June 27, 1977, houses a range of companies across multi-dimensional businesses.
It is one of the oldest pharmaceutical health care companies in India, and through its group companies it manufactures and markets pharmaceutical, molecular diagnostics, and electronics products in India and internationally. The Company produces a range of bulk drugs, pharmaceutical preparations and electronic instruments.
Pharmaceuticals segment is engaged in manufacture of drugs and formulations.
Electronics segment is engaged in manufacture of electronics instruments and services. In 1994, the company entered into a technical collaboration with Biobras, Brazil, to manufacture highly purified insulin injections. During the year 1997-98, the company formed a joint venture company, namely Sarabhai Piramal Pharmaceuticals Ltd with Piramal Enterprises Ltd for marketing of certain products under trademarks being used by the company.

About Sun Pharma Advanced Research Company Ltd

Sun Pharma Advanced Research Company Limited (SPARC) is a clinical stage bio-pharmaceutical company engaged in creating new drugs and delivery systems.
The Company works on innovation and new product development for global markets.
They undertake projects in research and technology for new chemical entities (NCE's) or new molecules, and novel drug delivery systems (NDDS). Sun Pharmaceutical Advanced Research Company Limited was incorporated on March 1, 2006 as an innovative and development company.
It commenced operations on March 22, 2006.
As per Scheme of Arrangement, the entire business undertaking of the Innovative Research & Development including Novel Drug Delivery System (NDDS) Division of Sun Pharmaceuticals Industries' Research & Development Undertaking was transferred and vested into the Company effective from February 28, 2007.

FAQs for the comparison of Ambalal Sarabhai Enterprises Ltd and Sun Pharma Advanced Research Company Ltd

Which company has a larger market capitalization, Ambalal Sarabhai Enterprises Ltd or Sun Pharma Advanced Research Company Ltd?

Market cap of Ambalal Sarabhai Enterprises Ltd is 239 Cr while Market cap of Sun Pharma Advanced Research Company Ltd is 5,262 Cr

What are the key factors driving the stock performance of Ambalal Sarabhai Enterprises Ltd and Sun Pharma Advanced Research Company Ltd?

The stock performance of Ambalal Sarabhai Enterprises Ltd and Sun Pharma Advanced Research Company Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Ambalal Sarabhai Enterprises Ltd and Sun Pharma Advanced Research Company Ltd?

As of May 18, 2026, the Ambalal Sarabhai Enterprises Ltd stock price is INR ₹31.26. On the other hand, Sun Pharma Advanced Research Company Ltd stock price is INR ₹162.15.

How do dividend payouts of Ambalal Sarabhai Enterprises Ltd and Sun Pharma Advanced Research Company Ltd compare?

To compare the dividend payouts of Ambalal Sarabhai Enterprises Ltd and Sun Pharma Advanced Research Company Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.